title: Nootropic nefiracetam inhibits proconvulsant action of peripheral-type benzodiazepines in epileptic mutant EL mice.
abstract: Piracetam and structurally related nootropics are known to potentiate the anticonvulsant effects of antiepileptic drugs. It remains to be seen, however, whether these nootropics inhibit proconvulsant actions of many toxic agents including Ro 5-4864, a specific agonist for peripheral-type benzodiazepine receptors (PBR). The present study was designed to address this issue using EL mice, an animal model of epilepsy. In behavioral pharmacological experiments, EL mice were highly susceptible to convulsions induced by Ro 5-4864 (i.p.) in comparison with nonepileptic DDY mice. Nefiracetam administered orally to EL mice inhibited spontaneous seizures. In DDY mice, convulsions induced by Ro 5-4864 were prevented by nefiracetam when administered by i.v. injection. Aniracetam (i.v.) was partially effective, but piracetam and oxiracetam were ineffective as anticonvulsants. Binding assay for brain tissues revealed a higher density of mitochondrial PBR in EL mice compared with DDY mice. Binding of the PBR ligands Ro 5-4864 to either EL or DDY mouse brain was inhibited by micromolar concentrations of these nootropic agents in the sequence of nefiracetam > aniracetam >> oxiracetam, piracetam. This rank order is identical to potency as anticonvulsants. These data suggest that nefiracetam may prevent toxic effects of PBR agonists through interacting with PBR.
authors.affiliation: Department of Neural Plasticity, Tokyo Institute of Psychiatry, Setagaya-ku, Tokyo 156-8585, Japan. nakamoto@prit.go.jp
authors.forename: Yurie
authors.initials: Y
authors.lastname: Nakamoto
authors.forename: Tadashi
authors.initials: T
authors.lastname: Shiotani
authors.forename: Shigeo
authors.initials: S
authors.lastname: Watabe
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Nabeshima
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Yoshii
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000633:toxicity; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003292:Convulsants / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000139:chemically induced / Q000235:genetics* / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008818:Mice, Neurologic Mutants; D018697:Nootropic Agents / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D011760:Pyrrolidinones / Q000378:metabolism / Q000494:pharmacology*; D018079:Receptors, GABA / Q000378:metabolism
chemical_list: D001570:Benzodiazepinones; C463819:Bzrp protein, mouse; D003292:Convulsants; D018697:Nootropic Agents; D011760:Pyrrolidinones; D018079:Receptors, GABA; C058876:nefiracetam; C028513:4'-chlorodiazepam